Biodexa's MTX110 shows promise in extending survival rates for pediatric DMG and adult rGBM, with progression-free survival results expected Q2 2024.

Biodexa Pharmaceuticals is developing MTX110 for Diffuse Midline Glioma (DMG) in pediatric patients and Recurrent Glioblastoma (rGBM) in adults, showing promise in extending survival rates beyond previous studies. Early trials indicate potential improvement in life expectancy for patients with these aggressive brain cancers, which typically have poor prognoses. Topline results for progression-free survival are expected in Q2 2024.

Articles

PR-inside

PharmiWeb

Biztoc

Street Insider

Finanz Nachrichten

Street Insider

-- show less --

Further Reading

Related Stories